ViiV Healthcare Presents Three-Year Results of Dovato (dolutegravir/lamivudine) in P-III TANGO Study for the Treatment of HIV at IDWeek 2021
- The P-III TANGO study evaluating the antiviral efficacy and safety of dolutegravir/lamivudine switching to a 2DR vs TAF based regimens in HIV-infected adults who had not experienced prior virologic failure
- The results showed that the 2-drug regimen demonstrated a non-inferior efficacy based on plasma HIV-1 RNA ≥50 c/mL @144wks. & resulted in no virologic failure compared to three drugs regimens in the ITT-E population- non-inferior virologic suppression (85.9% vs 81.7%) respectively- no resistance mutations were observed
- Additionally- no participants treated with dolutegravir/lamivudine met confirmed protocol-defined virologic failure @3yrs.
| Ref: Businesswire | Image: Viiv Healthcare
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at email@example.com